Terns Pharmaceuticals
TERN
TERN was delisted on the 4th of May, 2026.
45 hedge funds and large institutions have $134M invested in Terns Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 18 increasing their positions, 8 reducing their positions, and 13 closing their positions.
408% more capital invested
Capital invested by funds: $26.4M → $134M (+$108M)
125% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 8
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
22.3% more ownership
Funds ownership: 58.24% → 80.54% (+22%)
7% more funds holding
Funds holding: 42 → 45 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$13.8M |
| 2 |
O
OrbiMed
New York
|
+$13.7M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
+$12M |
| 4 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$7.62M |
| 5 |
DM
Deerfield Management
New York
|
+$6.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$3.13M |
| 2 |
SCM
Suvretta Capital Management
New York
|
-$3.07M |
| 3 |
AC
Antara Capital
New York
|
-$2.17M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.24M |
| 5 |
AAA
Affinity Asset Advisors
New York
|
-$995K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
E
51
Ergoteles
New York
| – | -$157K | -63,454 | Closed |
|
|
MAM
52
Marquette Asset Management
Minneapolis,
Minnesota
| – | -$144K | -57,876 | Closed |
|
53
Citadel Advisors
Miami,
Florida
| – | -$96K | -38,810 | Closed |
|
|
B
54
Bailard
Foster City,
California
| – | -$50K | -20,300 | Closed |
|
|
PI
55
PEAK6 Investments
Chicago,
Illinois
| – | -$123K | -14,097 | Closed |
|
|
CSS
56
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$6K | -2,428 | Closed |
|
TERN Hedge Fund Activity: Q3 2022 in Review
45 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Terns Pharmaceuticals (TERN) for Q3 2022, worth a combined $134M — up 408% from $26.4M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new TERN positions and 13 closed out — a net gain of 3 holders — while 18 added to existing stakes and 8 trimmed.
The largest buyer was VR Adviser, opening a new position worth an estimated $13.8M. The largest seller was RA Capital Management, exiting entirely with an estimated $3.13M sold.
- 45 institutional investors held Terns Pharmaceuticals (TERN) as of Q3 2022, up from 42 in Q2 2022.
- Funds reported $134M of Terns Pharmaceuticals stock for Q3 2022, up 408% quarter-over-quarter.
- 16 funds opened new Terns Pharmaceuticals positions in Q3 2022 and 13 closed out, a net change of +3 holders.
- The largest Terns Pharmaceuticals buyer in Q3 2022 was VR Adviser, an estimated $13.8M added.
- The largest Terns Pharmaceuticals seller in Q3 2022 was RA Capital Management, an estimated $3.13M sold.
Based on aggregated 13F filings for Q3 2022.